

## CURRICULUM VITAE

Revised: May 4, 2020

1. Name: Boadie Waid Dunlop, MD, MS
2. Office Address: Emory University School of Medicine  
Department of Psychiatry and Behavioral Sciences  
Room 347  
12 Executive Park Drive NE  
Atlanta, Georgia 30329  
  
Telephone: (404) 727-8969  
Fax: (404) 727-3700
3. E-mail Address: [bdunlop@emory.edu](mailto:bdunlop@emory.edu)
4. Current Titles and Affiliations:
  - a. Academic appointments:
    - i. Professor of Psychiatry (pending)  
Department of Psychiatry and Behavioral Sciences  
Emory University School of Medicine, Atlanta, Georgia  
September 2020 – present
  - b. Clinical appointments:
    - i. Director  
Mood and Anxiety Disorders Program  
Emory University  
Atlanta, Georgia, 2006 – present
    - ii. Medical Director  
Emory Healthcare Veterans Program  
Emory University  
Atlanta, Georgia, 2015 – present
5. Previous Academic and Professional Appointments:
  - a. Staff Psychiatrist  
Atlanta Veterans Affairs Medical Center  
Decatur, Georgia  
July 2001 – June 2003
  - b. Assistant Professor  
Department of Psychiatry and Behavioral Sciences

Emory University School of Medicine, Atlanta, Georgia  
July 2004 – August 2015

- c. Associate Professor of Psychiatry  
Department of Psychiatry and Behavioral Sciences  
Emory University School of Medicine, Atlanta, Georgia  
September 2015 – August 2020

6. Licensures/Boards:

Georgia Physician License Issued: 1998.

7. Specialty Boards:

American Board of Psychiatry and Neurology, continuous since 2002

8. Education:

1986-1990 BA, Washington University in St. Louis

1993-1997 MD, Mayo Medical School

2007-2012 MS, Clinical Research, Emory University Graduate School of Arts and Sciences

9. Post-graduate Training

1996 Epidemiology Intelligence Service internship, Centers for Disease Control, Atlanta

1997-2001 Psychiatry Residency, Emory University

2000-2001 Chief Resident, Atlanta Veterans Affairs Medical Center, Emory University Psychiatry Residency

2003-2004 Research Fellowship, Clinical Neuroscience, with Philip Ninan MD, Emory University

10. Committee Memberships:

a. National and International:

i. National Network of Depression Centers Board of Directors, 2009 – 2016

ii. Data Safety Monitoring Board, Chair, “LOSe PTSD” Multi-site Clinical Trial (PI: Murray Stein, University of California San Diego), 2016- present

b. Regional and State:

- i. American Foundation for Suicide Prevention, Atlanta Chapter, Board of Directors, 2013 – 2015
- c. Institutional:
  - i. Data Safety Monitoring Board, Co-Chair, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2006- present
  - ii. Clinical Investigators Advisory Committee, Emory University School of Medicine, member, 2008 -2016
  - iii. Clinical Research Operations Committee, Chair, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2008- 2015
  - iv. Psychiatry Residency Psychopharmacology Clinic Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2012 – present
  - v. Atlanta Clinical and Translational Science Institute, Scientific Advisory Committee, Emory University School of Medicine, member, 2013 - 2017
  - vi. Psychiatry-Neurology Research Integration Work Group, Co-Lead, Brain Health Initiative, Emory University School of Medicine, 2013 – 2016
  - vii. Faculty Development Funds Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2015 – 2017
  - viii. Brain Health Center Space Committee, Co-Chair, Emory University School of Medicine, 2015 – 2016
  - ix. Residency Education Subcommittee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2015 – 2020
  - x. Treatment Resistant Depression Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2016 – present
  - xi. Psychiatry Senior Research Council, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2017 – 2020
  - xii. Promotions Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2018 – present
  - xiii. Controlled Substances Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2018 - 2020
  - xiv. Research Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2018 – present

- xv. Translational and Clinical Research Stakeholder Team, Emory University School of Medicine Research Strategic Plan, Emory University, 2018 – 2019
- xvi. Research Recruitment and Retention Committee, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 2019- present

11. Peer Review Activities:

a. Grants

i. National and International:

1. Netherlands Organisation for Health Research and Development, 2014
2. United States Department of Defense Army Medical Research Command, Peer Reviewed Medical Research Program, 2014 & 2015
3. National Institutes of Health, Biomedical Computing and Health Informatics Study Section *ad-hoc* member, 2017- 2019
4. United States Department of Defense Joint Warfighter Medical Research Program, Military Operational Medicine Review Panel, 2018
5. Rosetrees Trust, Research Review Panel, United Kingdom, 2018
6. Fondazione Cariplo, Scientific Research on Major Depressive Disorder and Anxiety Syndrome Panel, Italy, 2019
7. National Institutes of Health, Biomedical Computing and Health Informatics Study Section, Charter member, 2019- present

ii. Institutional:

1. Emory University Scientific Advisory Committee, Atlanta Clinical and Translational Science Institute, 2013 – 2016
2. University of Michigan Depression Center Oscar Stern Award, 2015
3. Georgia Clinical and Translational Science Alliance, Emory University, KL2 reviewer, 2015
4. Emory University Synergy Awards, 2017

b. Manuscripts

1. *International Journal of Neuropsychopharmacology*, 2007
2. *Journal of Psychosomatic Research*, 2008
3. *Psychiatry Research*, 2008
4. *Journal of Clinical Psychopharmacology*, 2008 - present
5. *Expert Opinion in Pharmacotherapy*, 2009
6. *Journal of Psychopharmacology*, 2009
7. *Progress in Neurobiology*, 2009 - 2010
8. *CNS Spectrums*, 2010 – 2013

9. *Current Psychiatry*, 2010 – 2012
10. *Journal of the American Medical Association (JAMA)*, 2010 - 2011
11. *American Journal of Bioethics – Neuroscience*, 2011
12. *Behavioral Sciences*, 2012
13. *Contemporary Clinical Trials*, 2012
14. *Neuropsychopharmacology*, 2012
15. *Value in Health*, 2012
16. *CNS Drugs*, 2012 - 2014
17. *Depression and Anxiety*, 2012 - 2019
18. *Psychoneuroendocrinology*, 2013
19. *Journal of Affective Disorders*, 2013 - present
20. *Journal of Clinical Psychiatry*, 2013 – present
21. *JAMA Psychiatry*, 2014 - present
22. *Cochrane Collaboration, Depression, Anxiety, and Neurosis Group*, 2014
23. *Biological Psychiatry*, 2016 – present
24. *American Journal of Psychiatry*, 2016 – present

c. Book Prospectuses

1. Ghaemi, N, *Mood Disorders: A Clinical Textbook*, Oxford University Press, 2013
2. Schwartz T, *Practical Psychopharmacology: Basic to Advanced Principles*, Routledge, 2014
3. Bhala IP, Radhakrishnan R, Srihari V, Tampi RR. *50 Studies Every Psychiatrist Should Know*, Oxford University Press, 2018
4. Ansari A, Osseur DN. *Psychopharmacology: A Concise Overview for Students and Clinicians*, Oxford University Press, 2019

12. Consultantships/Advisory Boards:

- a. Cephalon, Provigil Advisory Board, 2007
- b. Pfizer, Evidence in Health presenter, 2007
- c. Imedex LLC, CME content developer and consultant, 2008 – 2010
- d. Bristol-Myers Squibb, Clinical Trial Design Advisory Board, 2009
- e. Pfizer, Lyrica for Generalized Anxiety Disorder Advisory Board, 2009
- f. Medavante, Principal Investigator Advisory Board, 2009 - present
- g. United Biosource Corporation, Symptom Rating Scale Instructor, 2010
- h. Bristol-Myers Squibb, COMET study Advisory Board, 2011
- i. Pfizer, Pristiq Advisory Committee, 2011
- j. Hoffman-LaRoche, Data Safety Monitoring Committee, 2012-2014
- k. Pfizer, Pristiq Advisory Committee, 2014
- l. Cohen's Veterans Bioscience Alliance for Modeling PTSD, Innovative Technologies and Uniform Practices (AMP IT UP), 2016

- m. Cohen's Veterans Bioscience Clinical Trials Network Workshop, 2017
- n. Myriad Neuroscience (previously Assurex Health), Scientific Advisory Board, 2018-2020
- o. Aptinyx, Inc. Consultant, 2018-2019
- p. Mol Dx, Palmetto GBA, Consultant, 2018-2019
- q. Sophren Therapeutics, Consultant, 2019
- r. Greenwich Biosciences, Scientific Advisory Board, 2019-2020
- s. Otsuka Pharmaceuticals, Scientific Advisory Board, 2020

13. Editorships and Editorial Boards:

- a. Associate Editor, Complicated Case Histories, *Psychopharmacology Bulletin*, 2007 – 2014
- b. Member, Editorial Board, *Depression and Anxiety*, 2012 – 2017
- c. Associate Editor, The Applied Armamentarium, *Focus: The Journal of Lifelong Learning in Psychiatry*, 2016 -- present

14. Honors and Awards:

- a. Academic All-American: 1988, 1989, 1990
- b. All-American, Honorable Mention, Swimming, 1987, 1988, 1990
- c. Phi Sigma Alpha (Political Science Honorary), 1990
- d. Phi Beta Kappa, 1990
- e. Washington University Gwendolyn Drew Award, 1990 (Most outstanding scholar-athlete of graduating class)
- f. Mayo Medical School, Mitchell D. Taylor Scholarship, 1993 – 1997
- g. Mayo Medical School, Harry Hoffman Scholarship, 1996
- h. Wyeth-Ayerst Resident Reporter Award, May 1999
- i. Career Directions Award, May 2000
- j. Future Leaders of Psychiatry Award, April 2002
- k. Fellowship, American Society of Clinical Psychopharmacology, 2006
- l. Career Development Institute Award, 2006
- m. New Investigator Award, New Clinical Drug Evaluation Unit annual meeting, 2009
- n. Distinguished Poster Award, International Society for CNS Clinical Trials and Methodology, 2011
- o. American College of Neuropsychopharmacology (ACNP) Travel Award, 2012
- p. Teacher of the Year, PGY-4s, Emory Department of Psychiatry and Behavioral Sciences, 2015
- q. Mentor of the Year for Research, Emory Department of Psychiatry and Behavioral Sciences, 2015
- r. Highlighted researcher, Researcher Appreciation Day, Emory University School of Medicine, 2017
- s. Highlighted educator, Educator Appreciation Day, Emory University School of Medicine, 2018

15. Society Memberships

- a. American Foundation for Suicide Prevention, 2013 - 2015

## 16. Clinical Service Contributions

- a. Directing the Mood and Anxiety Disorders Program, 2006- present
- b. Led the development of *Clinica Latina para el Tratamiento de la Depresion* at Grady Health Center, 2009-2013
  - This Spanish-language clinic provided an opportunity for Spanish-speaking subjects to receive psychopharmacological and psychotherapeutic treatment for major depression in their own language.
- c. Helped develop the IRB Sensitive Study Exemption for informed consents for research participants, 2011
- d. Manage a psychopharmacology treatment clinic of roughly 150 active patients, 2012- present
- e. Co-authored Emory Psychiatry Outpatient Clinician's Handbook, 2014

## 17. Community Outreach

### a. General

- i. National Depression Screening Day: Major Depressive Disorder, 2003
- ii. Skyland Trail Board of Directors: Advances in Psychiatry, 2004
- iii. Volunteer Coach, U5-U8 Soccer, Inter-Atlanta FC Blues, 2009-2014
- iv. Skyland Trial Board of Directors: Emerging Treatments for Mood Disorders, 2012
- v. Dekalb County Community Service Board, "Pharmacotherapy for PTSD: An Update and Look Toward the Future", 2012
- vi. Men's Division International: Suicide in Men, 2013
- vii. National Alliance for the Mentally Ill, Atlanta Chapter: Clinical Trials in Psychiatry, 2015
- viii. Volunteer Coach, Glenn School Basketball League, 2015-2016
- ix. Changing a Generation Baptist Church: Depression, 2017
- x. St. Philip AME Church: Community Brain Health Forum, 2018
- xi. New Mercies Christian Church: Mental Health and Wellness, 2018
- xii. Community Brain Health Forums, multiple sites around Atlanta, 2017-2019

### b. Media Appearances

- i. Everyday Health Internet radio. 2006.  
Discussion of how to intervene with a depressed family member.
- ii. CNN: House Call with Dr. Sanjay Gupta. March 15, 2008.  
Discussion with Dr. Gupta about severity of depression and when to use antidepressants.

<http://archives.cnn.com/TRANSCRIPTS/0803/15/hcsg.01.html>

- iii. Reach MD Internet radio. Multiple appearances January to May 2008. Discussions about treating anxiety, use of antidepressants, and effects of psychotherapy in the brain.  
<http://www.reachmd.com/xmradioquest.aspx?pid=3596>
- iv. CNN International. April 8, 2009.  
Discussion of mental health of Italian earthquake survivors.
- v. Web MD. 2009  
U.S. homes losing battle of the germs  
<http://www.webmd.com/women/news/20090714/us-homes-losing-battle-of-the-germs?page=3>
- vi. Seattle Times. February 8, 2010.  
Drivers, cars are ill-equipped when panic sets in.  
[http://seattletimes.com/html/business/technology/2011019699\\_apustoyota\\_driverpsychology.html](http://seattletimes.com/html/business/technology/2011019699_apustoyota_driverpsychology.html)
- vii. CBS Atlanta Channel 46. Better Mornings Atlanta. October 14, 2010.  
Discussion of trapped Chilean miners' mental health after rescue.  
[http://www.cbsatlanta.com/local-video/index.html?grabnetworks\\_video\\_id=4373140](http://www.cbsatlanta.com/local-video/index.html?grabnetworks_video_id=4373140)
- viii. Fox 5 Atlanta. May 29, 2012  
Recession, unemployment take toll on men.  
<http://www.myfoxatlanta.com/story/18642336/recession-unemployment-takes-toll-on-men#axzz33WFoGogT>
- ix. Fox 5 Atlanta. July 16, 2012  
With lousy economy, men struggling with depression.  
<http://www.myfoxatlanta.com/story/19035350/talking-with-your-husband-about-depression#axzz33WFoGogT>
- x. Web MD. September 7, 2012  
Tempted to quit antidepressants?  
<http://www.webmd.com/depression/features/antidepressants-take-time-to-work-time-to-quit>
- xi. CNN Health. December 3, 2012  
Treating PTSD with ecstasy  
[http://www.cnn.com/2012/12/03/health/ecstasy-ptsd-3/index.html?hpt=he\\_c1](http://www.cnn.com/2012/12/03/health/ecstasy-ptsd-3/index.html?hpt=he_c1)
- xii. CBS News. June 13, 2013  
Depression treatments: Brain scans may suggest best course.



<http://www.cbsnews.com/news/depression-treatments-brain-scans-may-suggest-best-course/>

- xiii. Ebix Health. November 2015. How to cope with seasonal sadness  
<http://ebixhealth.newsweaver.com/1ouc66236hmlwib88jh1o5?email=true&a=1&p=720957&t=133045>
- xiv. EverydayHealth. February 26, 2016  
Your 10 biggest antidepressant problems, solved  
<http://www.everydayhealth.com/depression/symptoms/biggest-antidepressant-problems-solved/>
- xv. EverydayHealth. May 8, 2017  
6 depression symptoms you shouldn't ignore  
<https://www.everydayhealth.com/depression/symptoms/depression-symptoms-you-shouldnt-ignore/>
- xvi. Barrons.com. February 8, 2019  
A genetic testing stock facing its own trial  
<https://www.barrons.com/articles/myriad-genetics-stocks-direction-hangs-on-psychiatric-debate-51549671974>
- xvii. Georgia Public Broadcasting. December 9, 2019  
Psychedelics for use in treating psychiatric disorders  
<https://www.gpbnews.org/post/when-it-comes-complex-ptsd-depression-research-turns-psychedelics-treatment>
- xviii. Channel 2 ABC News. February 13, 2020  
Emory looks into using psychedelic drugs as possible treatment for depression  
<https://www.wsbtv.com/news/local/mushrooms-therapy-emory-looks-into-using-psychedelic-drugs-possible-treatment-depression/KIQZD5CDHRB3PG5ZCI3SPJTEZQ/>

19. Formal Teaching:

a. Medical Student Teaching:

- i. Emory medical students Lecturer (3 hours/year) on Anxiety Disorders and Obsessive Compulsive Disorder, 2007- 2016
- ii. Emory Medical Student Oral Examiner, 2007-2012
- iii. Lincoln Memorial University, DeBusk College of Osteopathic Medicine medical students Lecturer (4 hours/year) on Mood and Anxiety Disorders, 2012-present
- iv. Emory Medical Student Research Poster judge, 2013

b. Graduate Programs:

i. Residency Programs

1. Individual lectures to Emory Psychiatry residents, 2001- present
2. Individual lectures to Emory Family Medicine residents, 2003-2010
3. Mock Oral Board examiner for PGY-3 and PGY-4 Psychiatry residents of Emory University and University of Pennsylvania, 2005-2008
4. Emory Psychiatry Residents Mood and Anxiety Disorders Module director (41 hours/year), 2006 – 2020

c. Other: Continuing Medical Education Program developer for MD Practice Guide.com

- i. "Managing Bipolar Disorder in the Clinical Setting," 2009
- ii. "Managing Depression in the Clinical Setting," 2010

20. Supervisory Teaching:

a. PhD Thesis Committees:

- i. Daniel Yoo, PhD, Psychology Doctoral Program, Emory University, 2013-2015
- ii. Jamie Kennedy, MA, Psychology Masters Program, Emory University, 2018-2020

b. Other

i. Faculty Mentorship

1. Vivanne Aponte-Rivera, MD, 2009-2013, Assistant Professor, Department of Psychiatry, Tulane University School of Medicine
2. Jeffrey J. Rakofsky, MD, 2009-present, Assistant Professor of Psychiatry and Behavioral Sciences, Emory University
3. Sarah Cook, MD, 2017-2019, Assistant Professor of Psychiatry and Behavioral Sciences, Emory University
4. Aliza Wingo, MD, 2018-present, Assistant Professor of Psychiatry and Behavioral Sciences, Emory University
5. Ali John Zarrabi, MD, 2020-present, Assistant Professor of Medicine, Emory University

ii. Masters of Public Health Students: 3-month practicum

1. Eric Hill, MPH, 2013
2. Yuqi Sun, MPH, 2014
3. Ruizhe Wu, MPH, 2017
4. Xingyue Huo, MPH, 2018

iii. Psychiatry Residents:

1. Psychodynamic Psychotherapy Supervisor for psychiatry residents, 2001-2012, one resident per year.
  2. Six-month Research Elective Supervisor, 2006, 2007, 2010, 2013, 2017, 2018
  3. Emory Psychiatry Resident Psychopharmacology Clinic supervisor, 2012 - present, 3 residents per year
- iv. Emory Discovery Student Mentor
1. Britta Maciuba, MD, 2012
  2. Philip Polychroniou, MD 2017-2018
- v. Undergraduate student research projects supervised:
1. Shezza Shagarabi (NET/Work program), 2013-2014: "Assessing the effects of major depression and antidepressants on social decision-making using an economic task."
  2. Danielle Moskow, 2014: "Impact of early crying during psychotherapy for depression on treatment outcomes."
  3. Margaret Quinn, 2015-2016: "Crying as an independent predictor of treatment outcome in Cognitive Behavior Therapy (CBT), regardless of gender, comorbid anxiety, or language/culture." *Summa cum laude* thesis.
  4. Maria Granros, 2018: "Recall accuracy for the symptoms of a major depressive episode among clinical trial participants."
  5. Ben Furman, 2019-2020: "Daily life stressors in the course of Major Depressive Disorder: Changes with treatment and potential predictor and moderator of treatment response." Highest honors thesis.
  6. Divyaansh Raj, 2019-2020: "Does Inflammation Damage White Matter Tracts in Patients with Major Depression." Highest honors thesis.
- vi. Mentorship of Graduate School Applicants:
1. Kallio Hunnicut-Ferguson, PhD, 2006-2007, Assistant Professor, Psychology, Emory University
  2. Melissa McKenzie, PhD, 2007-2009, Private Practice psychologist
  3. Ximena Marincic, MA, 2008-2010, Research coordinator, University of Miami
  4. Margo Aaron, MA, 2009-2011, Entrepreneur
  5. Christopher Vaughan, MBA, 2009-2011, Business Consultant
  6. Lauren Marx, PhD, 2009-2011, Private Practice psychologist
  7. Novall Khan, MA, 2009-2011, iOS Engineer,
  8. Jacqueline Larson, MA, 2010-2012, Social Research Specialist, University of North Carolina Charlotte Urban Institute,
  9. Rebecca Schneider, PhD, 2011-2013, Assistant Professor, Psychology, Emory University
  10. Joanna Kaye, PhD, 2012-2014. Private Practice psychologist
  11. Benjamin Johnson, 2012-2014, Clinical Psychology PhD program, Pennsylvania State University
  12. Lauren Burdine, 2013-2015, Medical Student, Boston University

13. Lara Alexander, 2013-2015, Medical Student, University of South Florida
14. Kathleen Helms OTR/L, 2014-2017, Occupational Therapist, Mayo Clinic
15. Jacqueline Gray, 2015-2017, Doctor of Psychology program, William James College
16. Andrea Wong, 2017-2019, Masters of Psychology program, Malaysia University
17. Gilbert Reed, 2018-2019, Medical Student, Medical College of Georgia
18. Amber Lechner, 2017 – 2020, Masters of Social Work Program, University of Georgia
19. Sarah Still, 2018 – 2020, Masters of Social Work Program, University of Georgia
20. Ayeesha Sayyad, 2018 – 2020, Masters of Public Health program, Georgia State University
21. Yasmin Anderson, 2019 – 2020, Medical Genetics PhD program, University of Georgia

21. Lectureships, Seminar Invitations, and Visiting Professorships:

a. National and International

- i. “Imaging the Effects of Genetic Polymorphisms of the Dopamine Transporter”, State University of New York Upstate Medical University, Visiting Professor, Psychiatry Grand Rounds, Albany NY, October, 2005
- ii. “Predicting Treatment Response in Major Depressive Disorder”, Grand Rounds, Drexel University Department of Psychiatry, Philadelphia, PA, September, 2011
- iii. “Who Studies Whom and How: Why clinical trials fail in mood and anxiety disorders”, Johnson and Johnson Neuroscience Grand Rounds, National WebEx, May, 2012
- iv. “Pharmacological Innovations for PTSD”, US Department of Veterans Affairs, National Webex, August, 2013
- v. “Integrating Biological and Psychological Research to Improve Understanding of Psychotherapeutic Treatments for Depression”, MQ Transforming Mental Health charity, London, England, December, 2013
- vi. “Treating Depression: How personal can we get?” University of Melbourne, Department of Psychiatry Grand Rounds, Melbourne, Australia, March, 2017
- vii. “Added Value of Combining Psychotherapy with Medication for Depression”, Mayo Clinic, Department of Psychiatry Grand Rounds, Rochester, MN, March 2017

b. Institutional

- i. “What to Choose for those with the Blues: Initial Choice of Treatment for Major Depressive Disorder”, Emory University Department of Psychiatry and Behavioral Sciences Grand Rounds, Atlanta, GA, March, 2011
  - ii. “Senior Researchers: Research Update”, Emory University Department of Psychiatry and Behavioral Sciences Grand Rounds, Atlanta, GA, September, 2012
  - iii. “Welcome to DSM 5”, Emory University Department of Psychiatry and Behavioral Sciences, Division of Psychology, Atlanta, GA, October, 2013
  - iv. “Scientific Justification for and Social Implications of Diagnostic Changes in the DSM-5”, Emory University Department of Psychiatry and Behavioral Sciences, Division of Psychology, Atlanta, GA, May, 2015
  - v. “From Depress-on to Depress-off: Personalizing Treatment and the Emory PReDICT Study Results”, Emory University Department of Psychiatry and Behavioral Sciences Grand Rounds, Atlanta, GA, June, 2015
  - vi. “Assessment and Treatment of Depression with and without Anxiety”, Emory University Department of Internal Medicine, Atlanta, GA, March, 2016
22. Invitations to National/International Conferences, Regional, and Institutional Conferences:
- a. National and International
    - i. “A Course Through the Mind: Neurocircuits in Anxiety Disorders”, Anxiety Disorders Association of America Annual Meeting, Miami, FL, April, 2004
    - ii. “Homology Between Pathophysiology and Symptoms in Major Depressive Disorder”, American Psychiatric Association Annual Meeting, Toronto, Canada, May 2004
    - iii. “Taming the Anxious Mind: How Psychotherapy and Medications Transform the Brain”, Anxiety Disorders Association of America Annual Meeting, Seattle, WA, March, 2005
    - iv. “From Brain to Bedside: Understanding the Clinical Interface of Cognition and Neurocircuitry of Depression”, American Psychiatric Association Annual Meeting, Philadelphia, PA, May, 2007
    - v. “The Impact of Patient Beliefs and Preferences on Outcomes in Major Depressive Disorder”, American Psychiatric Association Annual Meeting, San Francisco, CA, May, 2013
    - vi. “Recent Developments in the Treatment of Major Depressive Disorder: Successes, Failures, and Breakthroughs”, 18th Annual Central New York

Psychopharmacology and Addiction Psychiatry Update, Syracuse, NY, October, 2013

- vii. "Combined Treatments in Dysthymia. Specific weight of psychopharmacology and psychotherapy", Third International Symposium on Controversies in Psychiatry, Mexico City, Mexico, June 2014
- viii. "Emory PReDICT Study: Initial Presentation", Association for Behavioral and Cognitive Therapies Annual Meeting, Philadelphia, PA, November, 2014
- ix. "Fancy-pants Science in Well-Worn Trials: Revealing Problem Areas in Signal Detection", Anxiety Disorders Association of America Annual Meeting, Philadelphia, PA, April, 2016
- x. "Efficacy of the Corticotropin Hormone Type 1 Receptor Antagonist GSK561679 in Women with PTSD", Anxiety Disorders Association of America Annual Meeting, Philadelphia, PA, April, 2016
- xi. "Clinical and Neuroimaging Predictors of Remission in Treatment-Naive Depressed Patients", Anxiety Disorders Association of America Annual Meeting, Washington DC, April, 2018
- xii. "Artificial Intelligence in Medicine", Personalized Medicine Conference, Mayo Clinic, Rochester, MN, September, 2018
- xiii. "Making Drugs Magical Again: MDMA Enhancement of Psychotherapy for PTSD", American College of Psychiatrists Annual Meeting, Fort Lauderdale, FL, February, 2020

b. Regional

- i. "Mechanisms of Action of Psychotherapy in the Brain", Georgia Psychiatric Physicians Association Annual Meeting, Atlanta, GA, February, 2005
- ii. "Treatment Resistant Anxiety Disorders: Neurobiology and Treatment", Alabama Psychiatric Physicians Association Annual Meeting, Destin, FL, April, 2006
- iii. "What to Choose for those with the Blues: Initial Choice of Treatment for Major Depressive Disorder", Georgia Academy of Family Physicians Annual Meeting, Atlanta, GA, November, 2007
- iv. "Psychopharmacology Workshop", Georgia Psychological Association Fall Meeting, Atlanta, GA, November, 2010
- v. "The Edge of Psychopharmacology, 2012", Georgia Psychological Association Fall Meeting, Atlanta, GA, October, 2012

- vi. “Improving Adherence and Maintaining Remission in Major Depressive Disorder”, Virginia Academy of Family Physicians Annual Meeting, Wintergreen, NC, January, 2014 Annual Meeting, Philadelphia, PA, April, 2016
- vii. “Psychopharmacology of Treatment Resistant Depression”, Georgia Psychiatric Physicians Association Annual Meeting, Atlanta, GA, February, 2017
- viii. “Pharmacogenetic Testing in Psychiatry”, Georgia Psychiatric Physicians Association Annual Meeting, Atlanta, GA, February, 2018
- xiv. “Biology of Depression”, Georgia Department of Behavioral Health and Developmental Disabilities Spring Colloquium, Peachtree City, GA, April, 2018
- xv. “Overview of Pharmacogenomic Testing in Psychiatry”, University of Georgia College of Pharmacy 2020 Mental Health Symposium, Athens, GA, February, 2020

23. Research focus:

My research focuses on the neurobiology and psychopharmacological treatment of major depression, bipolar disorder, and anxiety disorders, particularly in identifying biological predictors of treatment response for personalized medicine. Secondary areas of research interest include clinical trials design and interpretation, clinical research ethics, and the integration of psychotherapy with medication.

24. Grant Support:

a. Active support:

1. Federally funded:

2. Contracts

- 1. Site PI. Acadia Research Grant. ACP-103-059. 6/18/19 - present  
*A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment.* \$18,057 per subject
- 2. Site PI. Acadia Research Grant. ACP-103-055. 9/23/19 - present  
*52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment.* \$17,335 per subject
- 3. Site PI. Compass Pathways. COMP001. 12/10/2019 – present  
The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD). \$22,954 per subject.
- 4. Site PI. Aptinyx. NYX-783-2004. 12/10/2019 - present

A Phase 2, Sequential Parallel Comparison, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Weekly and Daily Doses of NYX-783 in Subjects with Post-Traumatic Stress Disorder. \$11,622 per subject

b. Previous Support:

1. Federally funded:

1. Co-I, NIMH  
U01 MH063481-05 (PI: Rothbaum) 9/24/02 – 6/30/06 & 7/1/06 – 6/30/09  
*CBASP augmentation for treatment of chronic depression*. \$1,366,267
2. Co-I, NIMH  
R21 MH067939 (PI: Kilts) 7/1/04 - 4/30/06  
*Imaging the neural correlates of genetic risk for ADHD*. \$271,584
3. Co-I, NIMH  
P41RR013642-13 (PI: McDonald) 9/15/04 – 5/31/08  
*Optimization of transcranial magnetic stimulation for treatment-resistant depression*. \$1,261,884
4. Co-I, NIMH  
1R01MH073719 (PI: Mayberg) 09/01/06 – 08/31/10  
*Imaging Predictors of Treatment Response for Depression*. \$2,025,346
5. PI, NIMH  
KL2RR 025009 07/31/07 – 05/31/09  
*Neural Correlates of Loss Aversion in Major Depression (KL2)*. \$278,844
6. Co-I, NIMH  
P50 MH077083 (PI: Mayberg) 4/1/08 – 6/30/12  
*Predictors of Antidepressant Treatment Response: The Emory CIDAR (PReDICT)*. \$9,289,914
7. Co-I, NIMH  
RO1 MH080880 (PI: Craighead) 4/1/08 – 3/31/13  
*Predictors of treatment response, relapse, and recurrence in major depression*. \$6,619,011
8. PI, National NIMH  
K23 MH086690 7/7/09 – 3/31/13  
*Neural Correlates of Loss Aversion in Major Depression*. \$520,899
9. PI, NIMH  
U19 MH069056 (PI Mayberg; Project 5 PI: Dunlop) 9/4/09 – 8/31/14  
*Emory-MSSM-GSK-NIMH Collaborative Mood and Anxiety Disorders Initiative: Project 5. Evaluation of the efficacy of the CRF1 antagonist GSK561679 in women with post-traumatic stress disorder*. \$1,465,597 for year 5
10. Co-I, NCCAM  
R21AT007090 (PI: Rapaport) 9/30/10 – 08/31/13  
*Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder*. \$644,800
11. PI, NIH  
UL1TR000454 (PI:Stephens; Project PI: Dunlop) 4/30/13 – 4/30/14



- Using Positron Emission Tomography to Determine Why Patients with Major Depression Relapse Despite Maintenance Antidepressant Treatment.* \$30,000
12. Co-I, NIMH  
HHS-NIH-MH-2010-024 RAPID (PI: Fava) 8/01/12 – 11/30/14.  
*Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression.* \$250,820
  13. Co-I, NCCAM.  
R21AT007090 (PI: Rapaport) 5/1/13 – 4/28/15  
*Efficacy of Swedish massage therapy on cancer-related fatigue in cancer survivors.* \$275,000
  14. PI, NIMH  
R43MH097370 (Sub-award with Pax Neuroscience) 9/4/2013 – 8/31/16  
*A peripheral diagnostic biomarker for Major Depression.* \$344,132
  15. Co-I, NIH/NCCIH  
R01 AT008857-01 (PI: Rapaport) 07/01/2015 – 08/31/2018  
*Omega-3 Fatty Acids for MDD with High Inflammation: a Personalized Approach.* \$472,917
  16. Co-PI, NIMH  
R01MH108348-01A1 (Co-PIs: Kaddurah-Daouk, Dunlop) 7/6/16-3/31/20  
*Metabolomic Signatures Predictive of Outcomes to Treatments for Major Depression.* \$759,676 per year
  17. PI, NIMH  
2R01MH073719 (PI: Dunlop) 9/1/14- 6/30/19  
*Testing an imaging biomarker for treatment stratification in major depression.* \$830,805 per year

2. Contracts:

1. Co-I, Cephalon Research Grant. 6/21/2002 – 5/31/2004  
*A 12-week open-label study followed by a 24 –week double-blind discontinuation exploratory study to evaluate the effects of Gabitril (tiagabine hydrochloride) in patients with social anxiety disorder (SAD).* \$225,950
2. Site PI, AstraZeneca Research Grant. 1/1/2003 – 6/30/2004  
*A Multi-Center, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilisation Period (AMETHYST STUDY).* \$54,000
3. Co-I, UCB Pharma Research Grant. 8/1/2003 – 8/1/2005  
*A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of levetiracetam versus placebo for the treatment of social anxiety disorder (generalized type).* \$57,662
4. Co-I, Cephalon Research Grant. 3/11/2004 - 12/31/2005  
*A double-blind pilot study to evaluate the safety and efficacy of Provigil*

- (modafinil) at fixed/flexible doses, in conjunction with identified SSRIs, for the treatment of excessive sleepiness in patients with mild to moderate depression with attendant symptoms of sleepiness and fatigue. \$281,250
5. Site PI, AstraZeneca Research Grant. 3/23/2004 – 12/31/2007  
*A multicenter, open-label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (SEROQUEL) and risperidone (RISPERDAL) in the long-term treatment of patients with schizophrenia or schizoaffective disorder. \$216,300*
  6. Co-I, Wyeth Research Grant. 9/27/2004 – 9/27/2006  
*A multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of a flexible dose of DVS-233-SR in adult outpatients with major depressive disorder. \$22,080*
  7. Site PI, Novartis Research Grant. 2/2/2005 – 10/13/2006  
*A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of XBD-173 in patients with generalized anxiety disorder. \$30,142*
  8. Site PI, Bristol-Myers Squibb Research Grant. 2/3/2005 – 1/31/2009  
*A multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of aripiprazole as adjunctive therapy in the treatment of patients with major depressive disorder. \$320,040*
  9. Site PI, Forest Research Grant. 4/19/2005 – 3/31/2007  
*Fixed dose comparison of escitalopram combination in adult patients with major depressive disorder. \$15,888*
  10. Site PI, Cephalon Research Grant. 7/19/2005 – 5/19/2008  
*A 10-week randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Gabitril at 4, 8, and 12 mg/day in the treatment of adults with generalized anxiety disorder. \$170,375*
  11. Site PI, Bristol-Myers Squibb Research Grant. 6/5/2006 – 6/5/2008  
*A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder. \$285,000*
  12. Site PI, GlaxoSmithKline Research Grant. 12/01/06 – 12/31/10  
*CRS106139: A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed with Major Depressive Disorder. \$157,000*
  13. Site PI, Novartis Research Grant. 1/30/2007 – 3/20/2009  
*An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension. \$232,516*
  14. Site PI, Ono Pharmaceuticals Research Grant. 8/31/2007 – 8/31/2010  
*A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of ONO-2333MS in patients with recurrent major depressive disorder. \$342,210*
  15. Site PI, Takeda Research Grant. 7/30/2008 – 8/31/2009  
*A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses of Lu AA21004*

- in acute treatment of adults with generalized anxiety disorder. \$360,610*
16. Site PI, Wyeth Research Grant. 3/18/2009 – 3/18/2011  
*A multi-center, double-blind, randomized, placebo-controlled study to evaluate functional outcome in outpatients with major depressive disorder treated with desvenlafaxine succinate sustained release. \$58,944*
  17. Co-I, Organon Pharmaceuticals Research Grant. 6/5/2009 – 8/31/2010  
*A multi-center, double-blind, fixed-dose trial examining the efficacy and safety of Org 25935 versus placebo as augmentation to cognitive behavioral therapy in subjects with panic disorder. \$55,425*
  18. Site PI, Forest Research Grant. 07/08/09 – 12/31/10  
*A double-blind, placebo-controlled study of cariprazine (RGH-188) as adjunctive therapy in major depressive disorder. \$156,000*
  19. Site PI, Novartis Research Grant. 06/01/10 – 12/31/13  
*A 52-week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with Major Depressive Disorder (MDD). \$ 168,664*
  20. Site PI, Pfizer Research Grant. 08/20/10 – 03/19/11  
*A Multicenter, Parallel-Group, Randomized, 10-Week, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of Desvenlafaxine Succinate Sustained-release Formulation (DVS SR) in the Treatment of Peri- and Postmenopausal Women With Major Depressive Disorder. \$117,281*
  21. Site PI, Bristol-Myers Squibb Research Grant. 07/01/11 – 12/31/13  
*A Multicenter, Randomized, Double-blind, Active-Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression. \$153,183*
  22. Site PI, Bristol-Myers Squibb Research Grant. 11/7/2011 – 10/1/2013  
*A Multicenter, Double-blind, 58-Week Rollover Study to assess the Safety and Tolerability of BMS820836 in Patients with Treatment Resistant Depression. \$39,647*
  23. Site PI, Pfizer Pharmaceuticals Research Grant. 12/17/14 – 12/1/15  
*A randomized, double blind, placebo-controlled, paralel group phase 2 study to assess effects of PF-04457845 on bold functional MRI in subjects with PTSD. \$300,000*
  24. Site PI, Otsuka Pharmaceuticals Research Grant. 11/4/14 – 12/31/15  
*An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 mg/day tablets) as an Adjunctive Treatment in Adults with Major Depressive Disorder and Irritability. \$77,116*
  25. Site PI, AssureRx Health, Inc. Research Grant. 8/20/14 – 7/31/16  
*A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from a Major Depressive Disorder (MDD) and Having Had – Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic (ARX 1006). \$140,000*

26. Site PI, Janssen Research Grant. 1/1/2016 – 7/1/17  
*A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic antidepressant in Adults with Major Depressive Disorder.* \$45,000
27. Site PI, Axsome Research Grant. 6/29/16 – 4/1/18  
*A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder.* \$35,000
28. Site PI, Acadia Research Grant. 4/21/2017 – 4/20/27  
*A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder.* \$130,464
29. Site PI, Janssen Research Grant. 11/13/17 – 11/12/27  
*A Two-Stage, Multicenter, Double-Blind, Randomized, Parallel Group, Active- and Placebo-Controlled, Adaptive Dose Finding Study to Assess the Efficacy and Safety of JNJ 42847922 as Adjunctive Therapy to an Antidepressant in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy.* \$120,000
30. Site PI. Takeda Research Grant. 12/6/16 – 04/01/2020  
*Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder.* \$653,891
31. Site PI. Sage Therapeutics Research Grant. 217-MDD-303. 09/23/2019 – 04/01/2020  
*A Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult subjects with major depressive disorder.* \$15,000
32. Site PI. Sage Therapeutics Research Grant. 217-MDD-302. 12/18/2019 – 04/01/2020  
*A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of SAGE-217 with a Fixed, Repeated Treatment regimen on Relapse Prevention in Adults with Major Depressive Disorder.* \$15,000

## 25. Bibliography

### a. Published and Accepted Research Articles in Refereed Journals:

1. Rubin C, Esteban E, Kieszak S, Hill RH, **Dunlop B**, Yacovac R, Trottier J, Boylan K, Tomaszewski T, Pearce K. Assessment of human exposure and adverse human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996. *Environmental Health Perspectives*, 2002; 110 Suppl 6:1047-1051.
2. **Dunlop BW**, Sternberg M, Phillips LS, Anderson J, Duncan E. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. *Psychopharmacology Bulletin*, 2003; 37(3):99-117. (Reprinted in *Mental Fitness*, 2004; 3:54-65.)

3. **Dunlop BW**, Dunlop AL. Counseling via analogy: Improving patient adherence in major depressive disorder. *Primary Care Companion to the Journal of Clinical Psychiatry*, 2005; 7(6):300-303.
4. Duncan E, **Dunlop BW**, Boshoven W, Woolson S, Hamer R, Phillips L. Relative risk of glucose elevation during antipsychotic exposure in a VA population. *International Clinical Psychopharmacology*, 2007; 22(1):1-11.
5. Sharma B, **Dunlop BW**, Ninan PT, Bradley R. Use of dialectical behavior therapy in borderline personality disorder: A view from residency. *Academic Psychiatry*; 2007; 31(3):218-224.
6. **Dunlop BW**, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan, PT. Tiagabine for social anxiety disorder. *Human Psychopharmacology*, 2007; 22(4):241-244.
7. Dunlop AL, Graham T, Leroy Z, Glanz K, **Dunlop BW**. Impact of HIPAA authorization on the willingness of African-Americans to participate in clinical research. *Annals of Epidemiology*, 2007; 17:899-905.
8. **Dunlop BW**, Crits-Christoph P, Hirschowitz J, Evans DL, Solvason HB, Rickels K, Garlow SJ, Gallop RJ, Ninan PT. Co-administration of modafinil and an SSRI from the initiation of treatment for major depressive disorder with fatigue and sleepiness: A double-blind, placebo-controlled study. *Journal of Clinical Psychopharmacology*, 2007; 27(6):614-619.
9. Keller MB, Trivedi MH, Thase MT, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, **Dunlop BW**, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pederson R, Yan B, Ahmed S, Schmidt M, Ninan PT. The Prevention of recurrent episodes of depression with venlafaxine for Two Years (PREVENT) Study: Outcomes from the acute and continuation phases. *Biological Psychiatry*, 2007; 62(12):1371-1379.
10. Kornstein SG, Kocsis JH, Ahmed S, Thase M, Friedman ES, **Dunlop BW**, Yan B, Pedersen R, Ninan PT, Li T, Keller M. Assessing the Efficacy of Two Years of Maintenance Treatment With Venlafaxine ER 75 mg/d to 225 mg/d in Patients With Recurrent Major Depression: A Secondary Analysis of Data from the PREVENT Study. *International Clinical Psychopharmacology*, 2008; 23(6):357-363.
11. **Dunlop BW**, Self RS. Exercise for depression: Efficacy, safety and clinical trial implications. *Psychopharmacology Bulletin*, 2008; 41(4):65-75.
12. Duncan EJ, Woolson, SL, Hamer RM, **Dunlop BW**. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine and risperidone in a Veterans Affairs population. *International Clinical Psychopharmacology*, 2009; 24(4):204-213.
13. James GA, Kelley MA, Craddock RC, Holtzheimer PE, **Dunlop BW**, Nemeroff CB, Mayberg HS, Hu XP. Exploratory structural equation modeling of resting state fMRI: applicability of group models to individual subjects. *Neuroimage*, 2009; 45(3):778-787.

14. **Dunlop BW**, Banja J. A renewed defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. *Journal of Medical Ethics*, 2009; 35(6):384-389.
15. Rothschild AJ, **Dunlop BW**, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Ahmed S, Pedersen R, Keller MB. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. *Psychopharmacology Bulletin*, 2009; 42(3):5-20.
16. Banja JD, **Dunlop BW**. Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results. *American Journal of Bioethics*, 2009; 9:39-41.
17. **Dunlop BW**, Vaughan CL. Survey of investigators' opinions on the acceptability of interactions with patients participating in clinical trials. *Journal of Clinical Psychopharmacology*, 2010; 30(3):323-327.
18. **Dunlop BW**, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Ferguson J, Pederson R, Ahmed S, Ninan P, Keller M. Correlation between patient and clinician assessments of depression severity in the PREVENT study. *Psychiatry Research*, 2010; 177(1-2):177-183.
19. **Dunlop BW**, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan PT, Keller M, Trivedi MH. Concordance between clinician and patient ratings as predictors of response, remission and recurrence in major depressive disorder. *Journal of Psychiatric Research*, 2011; 45(1):96-103.
20. **Dunlop BW**, Betancourt Y, Binder EB, Heim C, Holsboer F, Ising M, McKenzie M, Mletzko T, Pfister H, Nemeroff, CB, Craighead WE, Mayberg HS. Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder. *Journal of Psychiatric Research*, 2011; 45(1):24-28.
21. Rakofsky JJ, Levy ST, **Dunlop BW**. Conceptualizing treatment nonadherence in patients with bipolar disorder and post-traumatic stress disorder. *CNS Spectrums*, 2011; 16(1) ePub.
22. Dunlop AL, Leroy ZC, Logue KM, Glanz K, **Dunlop BW**. Pre-consent education about research processes improved African Americans' willingness to participate in clinical research. *Journal of Clinical Epidemiology*, 2011; 64(8):872-877.
23. **Dunlop BW**, Reddy S, Yang L, Lubaczewski S, Focht K, Gucio-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: A double-blind clinical trial of desvenlafaxine versus placebo. *Journal of Clinical Psychopharmacology*, 2011; 31(5):569-576.
24. **Dunlop BW**, DeFife JA, Marx L, Garlow SJ, Ninan PT, Nemeroff CB, Lilienfeld SO. The effects of sertraline on psychopathic traits. *International Clinical Psychopharmacology*, 2011; 26(6):329-337.

25. **Dunlop BW**, Kelley ME, Mletzko TC, Delgado CV, Craighead WE, Mayberg HS. Depression beliefs, treatment preferences and outcomes in a randomized trial for major depressive disorder. *Journal of Psychiatric Research*, 2012; 46(3):375-381.
26. Rakofsky JJ, **Dunlop BW**. US psychiatric residents' treatment of patients with bipolar disorder. *Journal of Clinical Psychopharmacology*, 2012; 32(2):231-236.
27. **Dunlop BW**, Holland P, Bao W, Ninan P, Keller MB. Recovery and subsequent recurrence in patients with recurrent major depressive disorder. *Journal of Psychiatric Research*, 2012; 46(6):708-715.
28. **Dunlop BW**, Binder EB, Cubells JF, Goodman MG, Kelley ME, Kinkead B, Kutner M, Nemeroff CB, Newport DJ, Owens MJ, Pace TWW, Ritchie JC, Aponte Rivera V, Westen D, Craighead WE, Mayberg HS. Predictors of remission in depression to individual and combined treatments (PReDICT): Study protocol for a randomized controlled trial. *Trials*, 2012; 13:106.
29. **Dunlop BW**, Thase ME, Wun C, Fayyad R, Guico-Pabia C, Musgnung J, Ninan P. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: The importance of academic sites. *Neuropsychopharmacology*, 2012; 37(13):2830-2836.
30. Garlow SJ, **Dunlop BW**, Neyman K, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) with sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. *Journal of Psychiatric Research*, 2012; 46(11):1406-1413.
31. McGrath CL, Kelley ME, Holtzheimer PE, **Dunlop BW**, Craighead WE, Franco AR, Craddock RC, Mayberg HS. Toward a neuroimaging treatment selection biomarker for major depressive disorder. *JAMA Psychiatry*, 2013; 70(8):821-829.
32. Engelmann JB, Maciuba B, Vaughan C, Paulus MP, **Dunlop BW**. Primary posttraumatic stress disorder increases sensitivity to long term losses among patients with major depressive disorder. *PLoS One*, 2013; 8(10):e78292.
33. Clayton AH, Kornstein SG, **Dunlop BW**, Focht K, Musgnung J, Ramey T, Bao W, Ninan PT. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of peri- and postmenopausal women with major depressive disorder. *Journal of Clinical Psychiatry*, 2013; 74(10):1010-1017.
34. Aponte Rivera V, **Dunlop BW**, Ramirez C, Kelley ME, Schneider R, Blastos B, Larson J, Mercado F, Mayberg HS, Craighead WE. Enhancing Hispanic participation in mental health clinical research: Development of a Spanish-speaking depression research site. *Depression and Anxiety*, 2014; 31(3):258-267.

35. Choi KS, Holtzheimer PE, Franco AR, Kelley ME, **Dunlop BW**, Hu XP, Mayberg HS. Reconciling variable findings in white matter integrity in major depressive disorder. *Neuropsychopharmacology*, 2014; 39(6):1332-1339.
36. Issler O, Harmati S, Paul E, Maeno H, Navon I, Zwang R, Gil S, Mayberg HS, **Dunlop BW**, Menke A, Awatramani R, Binder EB, Deneris ES, Lowry CA, Chen A. MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy and intact serotonergic activity. *Neuron*, 2014; 83(2):344-360.
37. Kaye JL, **Dunlop BW**, Iosifescu DV, Mathew SJ, Kelley ME, Harvey PD. Cognition, functional capacity, and disability in women with posttraumatic stress disorder: examining the validity of self-reports. *Journal of Psychiatric Research*, 2014; 57(Oct):51-57.
38. McGrath CL, Kelley ME, **Dunlop BW**, Holtzheimer PE, Craighead WE, Mayberg HS. Pretreatment brain states identify likely nonresponse to standard treatments for depression. *Biological Psychiatry*, 2014; 76(7):527-535.
39. **Dunlop BW**, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. *Trials*, 2014; 15:240.
40. Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, **Dunlop B**, Davis M, Bradley B, Ressler KJ. Randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder (PTSD) in OEF/OIF war veterans. *American Journal of Psychiatry*, 2014; 171(6):640-648.
41. **Dunlop BW**, McCabe B, Eudicone JM, Sheehan JJ, Baker RA. How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. *Human Psychopharmacology: Clinical and Experimental*, 2014; 29(6):528-536.
42. Cuijpers P, Weitz E, Twisk J, Kuehner C, David D, DeRubeis RJ, Dimidjian S, **Dunlop BW**, Hegerel U, Jarrett RB, Kennedy SH, Mergl R, Miranda J, Mohr DC, Segal ZV, Siddique J, Vittengel JR, Hollon SD. Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: An "individual patient data" meta-analysis. *Depression and Anxiety*, 2014; 31(11):941-951.
43. **Dunlop BW**, Kaye JL, Youngner C, Rothbaum BO. Assessing treatment-resistant posttraumatic stress disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). *Behavioral Sciences*, 2014; 4(4):511-527.
44. **Dunlop BW**, Hill E, Johnson B, Klein DN, Gelenberg AJ, Rothbaum BO, Thase ME, Kocsis JH. Mediators of sexual functioning and marital quality in chronically



- depressed adults with and without a history of childhood sexual abuse. *Journal of Sexual Medicine*, 2015; 12(3):813-823.
45. Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, **Dunlop BW**, Mathew S, Khan A, Weisler R, Nelson C, Shelton R, Thase M, Lane R. Assessment of the efficacy and safety of BMS-820836 in patients with treatment resistant major depression: Results from two randomized, double-blind studies. *Journal of Clinical Psychopharmacology*, 2015; 35(4):454-459.
  46. **Dunlop BW**, Kelley ME, McGrath CL, Craighead WE, Mayberg HS. Preliminary findings supporting insula metabolic activity as a predictor of outcome to psychotherapy and medication treatments for depression. *Journal of Neuropsychiatry and Clinical Neurosciences*, 2015; 27(3):237-239.
  47. Weitz E, Hollon SD, Twisk J, van Straten A, David D, DeRubeis RJ, Dimidjian S, **Dunlop BW**, Faramarzi M, Hegerl U, Jarrett RB, Kheirkhah F, Kennedy SJ, Mergl R, Miranda J, Mohr DC, Rush AJ, Segal ZV, Siddique J, Simmons AD, Vittengl JR, Cuijpers P. Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-analysis. *JAMA Psychiatry*, 2015; 72(11):1102-1109.
  48. Menke A, Arloth J, Best J, Czamara D, Lucae S, **Dunlop BW**, Mletzko Crowe T, Garlow SJ, Nemeroff CB, Ritchie JC, Craighead WE, Mayberg HS, Rex-Haffner M, Holsboer F, Uhr M, Binder EB. Time-dependent effects of dexamethasone plasma levels on glucocorticoid receptor challenge tests. *Psychoneuroendocrinology*, 2016; 69(Jul):161-171.
  49. Rapaport MH, Schettler P, Larson ER, Edwards SA, **Dunlop BW**, Rakofsky JJ, Kinkead B. Acute Swedish massage monotherapy successfully remediates symptoms of generalized anxiety disorder: A proof of concept study, *Journal of Clinical Psychiatry*, 2016; 77(7):e883–e891.
  50. Vittengl JR, Jarrett RB, Weitz E, Hollon SD, Twisk J, Cristea I, David D, DeRubeis RJ, Dimidjian S, **Dunlop BW**, Faramarzi M, Hegerl U, Kennedy SH, Kheirkhah F, Kuehner C, Mergl R, Miranda J, Mohr DC, Rush AJ, Segal ZV, Siddique J, Simmons AD, Cuijpers P. Divergent outcomes in cognitive behavioral therapy and pharmacotherapy for adult depression. *American Journal of Psychiatry*, 2016; 173(5):481-490.
  51. Cuijpers P, Weitz E, Lamers F, Penninx, B, Twisk J, DeRubeis R, Dimidjian S, **Dunlop BW**, Jarrett R, Segal Z, Hollon S. Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression, *Depression and Anxiety*, 2017; 34(3):246-256.
  52. Rakofsky JJ, Garlow SJ, Haroon E, Hermida A, Young JQ, **Dunlop BW**. Assessing residents' confidence in the context of pharmacotherapy competence. *Academic Psychiatry*, 2017; 41(3):350-353.

53. Mataix-Cols D, Fernández de la Cruz L, Monzani B, Rosenfield D, Andersson E, Pérez-Vigil A, Frumento P, de Kleine RA, Difede J, **Dunlop BW**, Farrell LJ, Geller D, Gerardi M, Guastella A, Hofmann S, Hendriks GJ, Kushner MG, Lee F, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JA, Storch EA, Strole A, Tart C, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, DCS Anxiety Consortium, Davis M, Rück, C. D-cycloserine (DCS) augmentation of exposure-based cognitive-behavior therapy for anxiety, obsessive-compulsive, and post-traumatic disorders: Systematic review and meta-analysis of individual participant data. *JAMA Psychiatry*, 2017; 74(5):501-510.
54. **Dunlop BW**, Kelley ME, Aponte-Rivera V, Kinkead B, Mletzko-Crowe T, Ritchie JC, Nemeroff CB, Craighead WE, Mayberg HS. Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. *American Journal of Psychiatry*, 2017; 174(6):546-556.
55. **Dunlop BW**, Rajendra JK, Craighead WE, Kelley, ME, McGrath CL, Choi KS, Kinkead B, Nemeroff CB, Craighead WE, Mayberg HS. Functional connectivity of the subcallosal cingulate cortex identifies differential outcomes to treatment with cognitive behavior therapy or antidepressant medication for major depressive disorder. *American Journal of Psychiatry*, 2017; 174(6):533-545.
56. **Dunlop BW**, Binder, EB Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS. Corticotropin-releasing factor type 1 receptor antagonism is ineffective for women with posttraumatic stress disorder. *Biological Psychiatry*, 2017; 82(12):866-874.
57. Berg JM, Kennedy JC, Ramirez CL, Stewart LM, **Dunlop BW**, Nemeroff CB, Mayberg HS, Craighead WE. The structure of personality disorders within a depressed sample. *Personalized Medicine in Psychiatry*, 2017; 1-2:59-64.
58. Engelmann JB, Berns GS, **Dunlop BW**. Hyper-responsivity to losses in the anterior insula during economic choice scales with depression severity. *Psychological Medicine*, 2017; 47(16):2879-2891.
59. Alexander L, Oliver A, Burdine LK, Tang Y, **Dunlop BW**. Reported maladaptive decision-making styles in unipolar and bipolar depression and their change with treatment. *Psychiatry Research*, 2017; 257(Nov):386-392.
60. **Dunlop BW**, Gray J, Rapaport MH. Transdiagnostic Clinical Global Impression scoring for routine clinical settings, *Behavioral Sciences*, 2017; 7(3):40.
61. Young MB, Norrholm SD, Khoury LM, Jovanovic T, Rauch SAM, Reiff CM, **Dunlop BW**, Rothbaum BO, Howell, LL. Enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA) relies on signaling via serotonin transporters and 5-HT<sub>2A</sub> receptors. *Psychopharmacology*, 2017; 234(19):2883–2895.

62. **Dunlop BW**, Rakofsky JJ. Surveying psychiatrists' psychopharmacology practices across common clinical scenarios, *FOCUS: The Journal of Lifelong Learning in Psychiatry*, 2017; 15:445-449.
63. Carrillo-Roa T, Labermaier C, Weber P, Herzog DP, Lareau C, Santarelli S, Wagner KV, Rex-Haffner M, Harbich D, Scharf SH, Nemeroff CB, **Dunlop BW**, Craighead WE, Mayberg HS, Schmidt MV, Uhr M, Holsboer F, Sillaber I, Binder EB, and Müller MB. Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity, *PLOS Biology*, 2017; 15(12): e2002690.
64. Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH, Torres MA, **Dunlop BW**, Rakofsky JJ, Rapaport MH. Massage therapy decreases cancer-related fatigue: results from a randomized early phase trial, *Cancer*, 2018; 124(3):546-554.
65. Adhikarla V, **Dunlop BW**, Jarkas N, Goodman MM, Mayberg HS, Owens MJ, Nye JA. Test-retest reliability of the SERT imaging agent [11C]HOMADAM in healthy humans. *Journal of Nuclear Medicine*, 2018; 59(2):315-319.
66. O'Connell CP, Schatzberg AF, Nemeroff CB, Debattista C, Binder EB, **Dunlop BW**, Craighead WE, Mayberg HS, Williams, LM, Goldstein-Piekarski AN. Genetic variation in corticotropin releasing hormone binding protein predicts antidepressant outcomes, *American Journal of Psychiatry*, 2018; 175(3):251-261.
67. Fava M, Freeman MP, Flynn M, Hoepfner BB, Shelton R, Iosifescu DV, Murrugh JW, Mischoulon D, Cusin C, Rapaport MH, **Dunlop BW**, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Double-blind, proof-of-concept (POC) trial of low-field magnetic stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD), *Brain Stimulation*, 2018; 11(1):75-84.
68. Kennedy JC, **Dunlop BW**, Craighead LW, Nemeroff CB, Mayberg HS, Craighead WE. Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence. *Journal of Consulting and Clinical Psychiatry*, 2018; 86(2):189-199.
69. **Dunlop BW**, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE. Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder, *Journal of Affective Disorders*, 2018; 229:111-119.
70. Riva Posse P, Reiff C, Edwards J, Job G, Galendez G, Garlow S, Saah T, **Dunlop BW**, McDonald W. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. *Journal of Affective Disorders*, 2018; 236:291-297.
71. **Dunlop BW**, Wu R, Helms K. Performance of the adult ADHD Self-Report Scale-v1.1 in adults with major depressive disorder. *Behavioral Sciences*, 2018; 8(4):37.

72. Hodgins GE, Blommel JG, **Dunlop BW**, Iosifescu D, Mathew SJ, Neylan TC, Harvey PD. Placebo effects across self-report, clinician-rating, and objective performance tasks among women with post-traumatic stress disorder: Investigation of placebo response in a pharmacological treatment study of post-traumatic stress disorder. *Journal of Clinical Psychopharmacology*, 2018; 38(3):200-206.
73. Bousman CA, **Dunlop BW**. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. *The Pharmacogenomics Journal*, 2018; 18(5):613-622.
74. Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Flavin DH, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, **Dunlop BW**, The Mood Disorders Precision Medicine Consortium (MDPMC). Mapping depression rating scale phenotypes onto Research Domain Criteria (RDoC) to inform biological research in mood disorders. *Journal of Affective Disorders*, 2018; 238:1-7.
75. Polychroniou P, Mayberg HS, Craighead WE, Rakofsky JJ, Haroon E, Aponte Rivera V, **Dunlop BW**. Temporal profiles and dose-responsiveness of side effects with escitalopram and duloxetine in treatment-naïve depressed adults, *Behavioral Sciences*, 2018; 8(7):64.
76. Syed SA, Beurel E, Loewenstein DA, Lowell JA, Craighead WE, **Dunlop BW**, Mayberg HS, Dhabhar F, Dietrich D, Keane RW, de Rivero Vaccari JP, Nemeroff CB. Defective inflammatory pathways in never-treated depressed patients is associated with poor treatment response. *Neuron*, 2018; 99(5):914-924.
77. Kelley ME, **Dunlop BW**, Nemeroff CB, Kutner MH, Craighead WE, Mayberg HS. Response rate profiles for major depressive disorder: characterizing early response and longitudinal nonresponse. *Depression and Anxiety*, 2018; 35(10):992-1000.
78. Pape J, Carillo-Roa T, Rothbaum BO, Nemeroff, CB, Czamara D, Zannas AS, Iosifescu DV, Mathew SJ, Neylan TC, Mayberg HS, **Dunlop BW**, Binder, EB. DNA methylation biomarkers of response to a CRF1 receptor antagonist in women with posttraumatic stress disorder. *Clinical Epigenetics*, 2018; 10(1):136.
79. **Dunlop BW**, Polychroniou P, Rakofsky JJ, Nemeroff CB, Craighead WE, Mayberg HS. Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. *Psychological Medicine*. 2019; 49(11):1869-1878.
80. Gould F, **Dunlop BW**, Rosenthal JB, Iosifescu DV, Mathew SJ, Neylan TC, Rothbaum BO, Nemeroff CB, Harvey PD. Temporal stability of cognitive functioning and functional capacity in women with posttraumatic stress disorder. *Annals of Clinical Neuropsychology*, 2019; 34(4):539-547.
81. Maples-Keller JL, Jovanovic TJ, **Dunlop BW**, Rauch S, Yasinski C, Michopoulos V,

- Coghlan C, Norrholm S, Rizzo AS, Ressler K, Rothbaum BO. When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates, *Journal of Anxiety Disorders*, 2019; 61(Jan):89-97.
82. Bousman CA, Arandjelovic, K, Serafino G, Mancuso SG, Eyre HA, **Dunlop BW**. Pharmacogenetic decision support tools and symptom remission: A meta-analysis of prospective randomized controlled trials in major depressive disorder. *Pharmacogenomics*, 2019; 20(1):37-47.
83. Larson ER, Kinkead B, Edwards SA, Schettler PJ, **Dunlop BW**, Rakofsky JJ, Rapaport MH. Model structure for protocol adherence utilizing a manualized therapeutic massage intervention. *Journal of Complementary and Integrative Medicine*, 2019; 16(2): pii.
84. **Dunlop BW**, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE. Benefits of sequentially adding cognitive behavior therapy or antidepressant medication in non-remitting depressed adults. *American Journal of Psychiatry*, 2019; 176(4):275-286.
85. Greden JF, Parikh SV, Rothschild AJ, Thase ME, **Dunlop BW**, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of combinatorial pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, blinded, randomized, controlled study, *Journal of Psychiatric Research*, 2019; 111(Apr):59-67.
86. **Dunlop BW**, Granros M, Lechner AL, Mletzko-Crowe T, Nemeroff CB, Mayberg HS, Craighead WE. Recall accuracy for the symptoms of a major depressive episode among clinical trial participants, *Journal of Psychiatric Research*, 2019; 116(Sep):178-184.
87. Boschloo L, Bekhuis E, Borsboom D, Weitz ES, Reijnders M, DeRubeis RJ, Dimidjian S, Dunner DL, **Dunlop BW**, Hegerl U, Hollon SD, Jarrett RB, Kennedy SH, Miranda J, Mohr DC, Simons AD, Parker G, Petrak F, Herpertz S, Quilty LC, Rush AJ, Segal ZV, Vittengl JR, Schoevers RA, Cuijpers P. The symptom-specific efficacy of cognitive behavioral therapy versus antidepressant medication in the treatment of depression: Results from an individual patient data meta-analysis. *World Psychiatry*, 2019; 18(2):183-191.
88. Bhattacharyya S, Ahmed AT, Arnold M, Liu D, Luo C, Hongjie Zhu H, Mahmoudiandehkordi S, Neavin D, Athreya AP, Louie G, **Dunlop BW**, Frye MA, Wang L, Weinshilboum RM, Krishnan RR, Rush AJ, Kaddurah-Daouk, R. Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients, *Translational Psychiatry*, 2019;9:173.
89. Bhattacharyya S, **Dunlop BW**, Mahmoudiandehkordi S, Ahmed AT, Louie G, Frye MA, Krishnan RR, Rush AJ, Mayberg HS, Craighead WE, Kaddurah-Daouk, R. Pilot study of metabolomic clusters as state markers of major depression and outcomes to

CBT treatment, *Frontiers in Neuroscience*, 2019;13:926.

90. Thase ME, Parikh SV, Rothschild AJ, **Dunlop BW**, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Jablonski MR, Greden JF. Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug Interactions in a randomized controlled trial. *Journal of Clinical Psychiatry*, 2019;80(6). pii: 19m12910.
91. Rosenfield D, Smits JAJ, Hofmann SG, Mataix-Cols D, de la Cruz LF, Andersson E, Rück C, Monzani B, Pérez-Vigil A, Frumento P, Davis M, de Kleine RA, Difede J, **Dunlop BW**, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hendriks GJ, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Storch EA, Ströhle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Altemus M, Anderson P, Cukor J, Finck C, Geffken GR, Golfels F, Goodman WK, Gutner CA, Heyman I, Jovanovic T, Lewin AB, McNamara JP, Murphy TK, Norrholm S, Thuras P, Turner C, Otto MW. Changes in dosing and dose timing of D-Cycloserine explain its apparent declining efficacy for augmenting exposure therapy for anxiety-related disorders: An individual participant-data meta-analysis. *Journal of Anxiety Disorders*, 2019; 68:102149.
92. **Dunlop BW**, Parikh SV, Rothschild AJ, Thase ME, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Logan J, Traxler P, Li J, Johnson H, Greden JF. Comparing sensitivity to change using the 6-item versus the 17-item Hamilton Depression Rating Scale in the GUIDED randomized controlled trial. *BMC Psychiatry*. 2019;19(1):420.
93. Maples-Keller JL, Rauch SAM, Jovanovic T, Yasinski CW, Goodknight JM, Sherrill A, Black K, Michopoulos V, **Dunlop BW**, Rothbaum BO, Norrholm SD. Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders, *Journal of Anxiety Disorders*, 2019; 68:102147.
94. Hershenberg R, McDonald WM, Crowell A, Riva-Posse P, Craighead WE, Mayberg HS, **Dunlop BW**. Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression. *Journal of Affective Disorders*, 2020; 266:22-29.
95. **Dunlop BW**, Still S, LoParo D, Aponte-Rivera V, Johnson BN, Schneider RL, Nemeroff CB, Mayberg HS, Craighead WE. Somatic symptoms in treatment-naïve Hispanic and non-Hispanic patients with major depression. *Depression and Anxiety*, 2020; 37(2):156-165.
96. Jovanovic T, Duncan EJ, Kaye J, Garza K, Norrholm SD, Inslicht S, Neylan T, Mathew S, Iosifescu D, Rothbaum BO, Mayberg H, **Dunlop BW**. Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. *Psychophysiology*, 2020;57(1):e13356.

97. Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, Louie G, Skime MK, Wang L, Riva-Posse P, McDonald W, Bobo WV, Craighead WE, Krishnan R, Weinshilboum RM, **Dunlop BW**, David S, Millington DS, Rush AJ, Frye MA, The Mood Disorders Precision Medicine Consortium (MDPMC), Kaddurah-Daouk R. Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes, *Journal of Affective Disorders*, 2020; 264:90-97.
98. Thomas M, Coope A, Falkenberg C, **Dunlop BW**, Czamara D, Provencal N, Craighead WE, Mayberg HS, Nemeroff CB, Binder EB, Nieratschker V. Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms. *Journal of Psychiatric Research*, 2020; 120:154-162.
99. Shelton RC, Parikh SV, Law RA, Rothschild AJ, Thase ME, **Dunlop BW**, DeBattista C, Conway C, Forester BP, Macaluso M, Hainc DT, Aguilar AL, Brown K, Lewis DJ, Jablonski MR, Greden JF. Combinatorial pharmacogenomic algorithm is predictive of citalopram and escitalopram metabolism in patients with major depressive disorder. *Psychiatry Research*, 2020, in press.
100. Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, Rothschild, AJ, Thase ME, **Dunlop BW**, DeBattista C, Conway C, Shelton RC, Macaluso M, Li J, Traxler P, Logan J, Brown L, Dechairo B, Greden JF. Combinatorial pharmacogenomic testing improves outcomes for patients with geriatric depression, *American Journal of Geriatric Psychiatry*, 2020, in press.
101. Kappelmann N, Rein M, Fietz J, Mayberg HS, Craighead WE, **Dunlop BW**, Nemeroff CB, Keller M, Klein DN, Arnow BA, Husain N, Jarrett RB, Vittengl JR, Menchetti M, Gordon Parker G, Barber JP, Bastos AG, Dekker J, Peen J, Keck ME, Kopf-Beck J. Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a symptom-oriented therapy (SOrT) metric for a personalised psychiatry, *BMC Psychiatry*, 2020, in press.

b. Manuscripts submitted:

1. Halldorsdottir T, Czamara D, Carrillo-Roa T, Rajendra J, Nemeroff C, **Dunlop BW**, Craighead WE, Mayberg HS, Binder EB. The interaction of FKBP5 genotype with childhood abuse reproducibly predicts comorbid depression and anxiety, *submitted*.
2. Rauch SM, Yasinski CW, Post LM, Jovanovic T, Norrholm S, Sherrill AM, Michopoulos V, Maples-Keller JL, Black K, Zwiebach L, **Dunlop BW**, Loucks L, Rothbaum BO. An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: retention, predictors, and patterns of change, *submitted*
3. Lopez JP, Brivio E, Santambrogio A, De Donno C, Kos A, Peters M, Rost N, Czamara D, Brückl TM, Roeh S, Pöhlmann ML, Engelhardt C, Ressler A, Stoffel R, Reincke M, Fassnacht M, Mayberg HS, Craighead WE, **Dunlop BW**, Nemeroff CB, Binder EB, Schmidt MV, Zeisel A, Theis FJ, Beuschlein F, Andoniadou CL, Chen A.

The neuroendocrine stress response at single-cell resolution reveals adrenal ABCB1 as key regulator of chronic stress activity, *submitted*.

4. Rakofsky JJ, Talbot, TB, **Dunlop BW**. A virtual standardized patient-based assessment tool to evaluate psychiatric residents, *submitted*.

c. Review articles:

1. Ninan PT, **Dunlop BW**. Neurobiology and etiology of panic disorder. *Journal of Clinical Psychiatry*, 2005; 66(Suppl 4):3-7.
2. **Dunlop BW**, Nemeroff CB. The role of dopamine in the pathophysiology of depression. *Archives of General Psychiatry*, 2007; 64(3):327-337.
3. **Dunlop BW**, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression. *Primary Care Companion to the Journal of Clinical Psychiatry*, 2008; 10(3):222-228.
4. **Dunlop BW**, Aaron MH. Response to treatment with placebo, medication or psychotherapy for severe, non-psychotic major depressive disorder. *Current Psychiatry Reviews*, 2010; 6:28-45.
5. Rakofsky JJ, **Dunlop BW**. Treating non-specific anxiety and anxiety disorders in patients with bipolar disorder: a review. *Journal of Clinical Psychiatry*, 2011; 72(1):81-90.
6. Rakofsky JJ, Ressler KJ, **Dunlop BW**. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. *Molecular Psychiatry*, 2011; 17(1):22-35.
7. **Dunlop BW**, Mansson E, Gerardi M. Pharmacological innovations for posttraumatic stress disorder and medication-enhanced psychotherapy. *Current Pharmaceutical Design*, 2012; 18:5645-5658.
8. **Dunlop BW**, Schneider R, Gerardi M. State of the art treatment of panic disorder. *Current Psychiatry*, 2012; 11:36-44.
9. Rakofsky JJ, **Dunlop BW**. Do alcohol use disorders destabilize the course of bipolar disorder? *Journal of Affective Disorders*, 2013; 145(1):1-10.
10. **Dunlop BW**, Scheinberg K, Dunlop AL. Ten ways to improve the treatment of depression and anxiety in adults. *Mental Health and Family Practice*, 2013; 10(3):175-181.
11. Craighead WE, **Dunlop BW**. Combination psychotherapy and antidepressant medication for depression: For whom, when and how. *Annual Review of Psychology*, 2014; 65:267-300.



12. Rakofsky JJ, **Dunlop BW**. Review of nutritional supplements in the treatment of bipolar depression. *Depression and Anxiety*, 2014; 31(5):379-390.
13. **Dunlop BW**, Mayberg HS. Neuroimaging-based biomarkers for treatment selection in major depressive disorder, *Dialogues in Clinical Neuroscience*, 2014; 16(4):507-518.
14. Rakofsky JJ, **Dunlop BW**. Treatment of bipolar mania in the outpatient setting: Risk vs reward. *Current Psychiatry*, 2014; 13(11):38-46.
15. Rakofsky JJ, **Dunlop BW**. The over-under on misdiagnosis of bipolar disorder: A systematic review, *Current Psychiatry Reviews*, 2015; 11(4):222-234.
16. **Dunlop BW**. Evidence-based applications of combination psychotherapy and pharmacotherapy for depression. *FOCUS: The Journal of Lifelong Learning in Psychiatry*, 2016(2); 14:156-173.
17. **Dunlop BW**, Wong A. The hypothalamic-pituitary-adrenal axis in PTSD: pathophysiology and treatment interventions. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2019; 89:361-379.
18. Hack LM, Fries GR, Eyre HA, Bousman C, Singh AB, Quevedo J, Baune BT, **Dunlop BW**. Moving pharmacoepigenetics tools for depression toward clinical use. *Journal of Affective Disorders*, 2019; 249:336-346.
19. Rakofsky JJ, **Dunlop BW**. Nothing to sneeze at: The effects of upper respiratory infections on mood disorders. *Current Psychiatry*, 2019;18(7):29-34.

d. Book Chapters:

1. **Dunlop BW**, Nihalani N. Substrates of sadness: The pathophysiology of depression. *Depression: Treatment Strategies and Management*, 2006, Schwartz TL, Peterson T, eds. Taylor and Francis, London, pp. 9-40.
2. **Dunlop BW**, Garlow S, Nemeroff CB. The neurochemistry of depressive disorders: Clinical studies. *Neurobiology of Mental Illness*, 3<sup>rd</sup> Ed., 2009, Charney D, Nestler EJ, eds. Oxford University Press, New York, pp. 435-460.
3. **Dunlop BW**, Nemeroff CB. Depression: Neuroscientific investigations. *Handbook of Neuroscience for the Behavioral Sciences*, 2009, Berntson G, Cacioppo JT, eds. John Wiley and Sons, Hoboken, NJ, pp. 1060-1089.
4. **Dunlop BW**, Nemeroff CB. The role of dopamine in the pathophysiology and treatment of major depressive disorder. *The Dopamine Handbook*, 2010, Iversen LL, Iversen SD, Dunnett SB, Björklund A, eds. Oxford University Press, New York, pp. 572-589.

5. Mletzko TC, **Dunlop BW**. The transformation of post-traumatic stress disorder: From neurosis to neurobiology. *Anxiety and Related Disorders*, 2011, Szirmai A, ed. InTech, Rijeka, Croatia, pp.151-190.
6. **Dunlop BW**, Lecrubier Y, Fossati P. Pharmacology and neuroimaging of antidepressant action. *Handbook of Clinical Neurology, No. 106*, 2012, Schlaepfer TE, Nemeroff CB eds. Elsevier, Amsterdam, pp. 643-657.
7. Rakofsky JJ, **Dunlop BW**. Psychiatric treatment of bipolar disorder: The case of Janice. *Case Studies in Clinical Psychological Science*, 2013, O'Donohue W, Lilienfeld SO, eds. Oxford University Press, New York, pp. 109-136.
8. Craighead WE, Johnson BN, Carey S, **Dunlop BW**. Psychosocial treatments for major depressive disorder. *A Guide to Treatments that Work, 4th Ed*, 2015, Nathan PE, Gorman JM, eds. Oxford University Press, New York, pp. 381-408.
9. **Dunlop BW**, Ressler KJ, Rothbaum BO. Pharmacological mechanisms of modulating fear and extinction. *Anxiety Disorders: Translational Perspectives on Diagnosis and Treatment*, 2015. Pine D, Ressler KJ, Rothbaum BO, Muskin A, eds. Oxford University Press, New York, pp. 367-385.
10. **Dunlop BW**, Davidson JRT. Pharmacotherapy for posttraumatic stress disorder. *The American Psychiatric Association Textbook of Anxiety, Trauma and OCD-related Disorders*, 2020. Simon N, Hollander E, Rothbaum BO, Stein DJ, eds. American Psychiatric Association, Washington D.C., pp. 519-541.
11. **Dunlop BW**, Medeiros Da Frota Ribeiro C. Randomized controlled trials and the efficacy of psychotropic medications. *NeuroPsychopharmacotherapy*, 2020. Riederer P, Laux G, Mulsant B, Le W, Nagatsu T, eds. Springer, New York, New York, pp. 1-56. DOI: 10.1007/978-3-319-56015-1\_4-1.

e. Books edited and written:

1. Ninan PT, **Dunlop BW**. *Contemporary Diagnosis and Management of Anxiety Disorders*. HHC Books, Newtown, PA, 2006.

f. Other Publications:

1. **Dunlop BW**, Ninan PT. Pharmacologic considerations in the treatment of severe depression. *Medscape Psychiatry and Mental Health*, 2003; 8, posted 10/10/2003. <http://www.medscape.com/viewarticle/462603>
2. Ninan PT, **Dunlop BW**. Contemporary choices in the short-term pharmacologic management of depression and anxiety. *Primary Psychiatry*, 2005; 12(4,Suppl 2):1-11.
3. **Dunlop BW**, Mayberg HS. Neuroimaging advances for depression. *Cerebrum*, 2017; 141-150.

g. Editorials:

1. **Dunlop BW**. Lost in translation: Be leery of lay language. *Current Psychiatry*, 2007; 6:102.
2. **Dunlop BW**. Should sensitive information from clinical trials be included in electronic medical records? *JAMA*, 2010; 304(6):685-686.
3. Aponte-Rivera VR, **Dunlop BW**. Public health consequences of state immigration laws. *Southern Medical Journal*, 2011; 104(11):718-719.
4. **Dunlop BW**, Mletzko T. Will current socioeconomic trends produce a depressing future for men? *British Journal of Psychiatry*, 2011; 198(3):167-168.
5. **Dunlop BW**. Ringing the bell to save the bereavement exclusion. *Psychiatric Times*, 2012; 29(9):8-9.
6. **Dunlop BW**. Depressive recurrence on antidepressant treatment (DRAT): Next step options. *Current Psychiatry*, 2013(5); 12:54-55.
7. **Dunlop BW**, Rakofsky JJ, Rapaport MH. A simple question answered: Adding moderate-dosage lithium does not help patients with bipolar disorder. *American Journal of Psychiatry*, 2013; 170(1):9-11.
8. **Dunlop BW**. Ziprasidone monotherapy is ineffective for bipolar-associated anxiety. *Evidence Based Mental Health*, 2014; 17(4):109.
9. **Dunlop BW**, Rapaport MH. Antidepressant signal detection in the clinical trials vortex. *Journal of Clinical Psychiatry*, 2015; 76(5):e657-e659.
10. **Dunlop BW**. Prediction of treatment outcomes for major depressive disorder. *Expert Review of Clinical Pharmacology*, 2015; 8(6):669-672.
11. **Dunlop BW**, Rapaport MH. When should a patient be declared recovered from a major depressive episode? *Journal of Clinical Psychiatry*, 2016; 77(8):e1026–e1028.
12. **Dunlop BW**. How shall I diagnose thee? Let me count the ways. *Biological Psychiatry*, 2017; 82(5):306-308.
13. **Dunlop BW**. Pharmacogenetic decision support tools: A component of precision medicine for psychiatry? *FOCUS: The Journal of Lifelong Learning in Psychiatry*, 2017; 15(suppl):3-4.
14. **Dunlop BW**. Imaging the future of major depression, *FOCUS: The Journal of Lifelong Learning in Psychiatry*, 2018; 16(4):3s.
15. **Dunlop BW**, Rothbaum BO Medication-assisted psychotherapy for PTSD.

*Psychiatric Quarterly*, 2019; 3(3): 1-15.

16. **Dunlop BW**. Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients. *Brazilian Journal of Psychiatry* 2020; 42(2):111-112.

h. Letters to the Editor

1. **Dunlop BW**, Garlow SJ, Ninan PT. Psychosocial context of antidepressant response. *Biological Psychiatry*, 2005; 57(3):314.
2. **Dunlop BW**. An additional consideration for comparisons of antidepressants versus placebo. *Journal of Clinical Psychopharmacology*, 2010; 30(5):641-642.
3. Rakofsky JJ, **Dunlop BW**, Beyer JL, Oliver AM, Mansson EE, Sancheti MT, Harvey PD. Cognitive effects of quetiapine XR in patients with euthymic bipolar disorder. *Journal of Clinical Psychopharmacology*, 2014; 34(3):383-384.
4. Rakofsky JR, Tang Y, **Dunlop BW**. Depression worsening associated with lorcaserin: A case report. *Journal of Clinical Psychopharmacology*, 2015; 35(6):747-749.
5. O'Connell CP, Goldstein-Piekarski AN, Nemeroff CB, Schatzberg AF, Debattista C, Carrillo-Roa T, Binder EB, **Dunlop BW**, Craighead WE, Mayberg HS, Williams LM. More research needed on the association between genotype and antidepressant response: Response to Fabbri et al. *American Journal of Psychiatry*, 2018; 175(6):576–577.
6. Greden JF, Parikh SV, Rothschild AJ, Thase ME, **Dunlop BW**, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. *Journal of Psychiatric Research*, 2019; 114:211-213.